【摘 要】
：
Background Multiple myeloma (MM) is a tumor of b cell origin.It is estimated that the bones are involved at presentation in 70 ％to 100 ％of patients.Spinal lesions with marked destruction are common si
【机 构】
：
Clinical center Ni(s)
【出 处】
：
The 35th World Congress of the International Society of Hema
论文部分内容阅读
Background Multiple myeloma (MM) is a tumor of b cell origin.It is estimated that the bones are involved at presentation in 70 ％to 100 ％of patients.Spinal lesions with marked destruction are common site of compression fractures in with MM due to osteoporosis which results from both the molecular pathophysiology of the disease and frequent use of corticosteroids in medical treatment.
其他文献
Objective Novel agents-based anti-myeloma regimens including thalidomide and bortezomib have significantly improved myeloma treatment.However,it remains unclear whether patients will benefit more from
Objective High altitude polycythemia (HAPC) is characterized by excessive erythrocytes and enhanced angiogenesis,which is caused by environmental factors such as hypoxia and cold at high altitude.Howe
Introduction Cytogenetic abnormality plays an important role in prognosis of patients with multiple myeloma (MM).Conventional cytogenetic assay reveals limited results.In this study,we performed inter
Background Multiple myeloma (MM) is a plasma-cell malignancy manifested accumulation of abnormal plasma cells in the bone marrow.The purpose of this study is to evaluate the prognosis in patients with
Purpose Global change in protein turnover (protein degradome) constitutes a central part of cellular responses to intrinsic or extrinsic stimuli.However,profiling protein degradome remains technically
Tumor initiating cells play important roles in multiple myeloma (MM) progression,relapse,recurrence,and are critical target for therapy.However,quite few agents have been shown to target tumor initiat
Objective The aim of this meta-analysis of data from phase Ⅲ studies is to characterize efficacy and safety of bortezomib-based versus nonbortezomib-based post-transplantation therapy in patients with
The PAD regime,composed of bortezomib,adriamycin and dexamethasone,improves the outcomes of patients with advanced multiple myeloma (MM),but at the same time produces high frequency of serious toxic s
Heat shock protein 90 (HSP90) is one of the most active molecular chaperones in cell,participating in cellular stress response as well as client protein maturation and stabilization.Cdc37 (cell divisi
Objective To define the role of autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM) in the era of novel agents,we analyzed the follow-up data in patients treated with